Table 1.

Characteristics of the clinical trials of apatinib for molecular targeted therapy in tumor

Study	Trial	Design	Tumor type	Outcomes (apatinib vs placebo)
Li et al12	Phase I	Dose escalation	Advanced solid tumors	MTD: 850 mg qd Recommended dose: 750 mg qd
Li et al22	Phase II	Randomized, placebo-controlled, parallel-arm	Gastric cancer	mPFS: 3.67a vs 1.40 months mPFS: 3.20b vs 1.40 months mOS: 4.83a vs 2.50 months mOS: 4.27b vs 2.50 months
Hu et al25	Phase II	Prospective, open-label, single arm	Triple-negative breast cancer	mPFS: 3.3 months mOS: 10.6 months
Hu et al24	Phase II	Multicenter, open-label, single arm	Non-triple-negative breast cancer	mPFS: 4.0 months mOS: 10.3 months
Zhang et al33	Phase II	Multicenter, randomized, placebo-controlled	Non-small-cell lung cancer	mPFS: 4.7 vs 1.9 months
Qin34	Phase III	Randomized, multicenter, double-blind, placebo-controlled	Gastric cancer	mOS: 195 vs 140 days mPFS: 78 vs 53 days

Notes:

^a850 mg of apatinib qd;

^bapatinib 425 mg bid.

Abbreviations: MTD, maximum tolerated dose; mPFS, median progression-free survival; mOS, median overall survival; bid, twice a day; qd, once a day.